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Key Points
• Antibodies causing FNAIT
have decreased Fc
fucosylation, unlike in
refractory thrombocytopenia.
• Decreased Fc fucose
increases affinity to
FcgRIIIa/b, enhances
platelet phagocytosis, and
correlates with increased
disease severity.
Immunoglobulin G (IgG) formed during pregnancy against human platelet antigens
(HPAs) of the fetus mediates fetal or neonatal alloimmune thrombocytopenia (FNAIT).
Because antibody titer or isotype does not strictly correlate with disease severity, we
investigated bymass spectrometry variations in the glycosylation at Asn297 in the IgGFc
because the composition of this glycan can be highly variable, affecting binding to
phagocyte IgG-Fc receptors (FcgR). We found markedly decreased levels of core
fucosylation of anti-HPA-1a–specific IgG1 from FNAIT patients (n 5 48), but not in total
serum IgG1. Antibodies with a low amount of fucose displayed higher binding affinity to
FcgRIIIa andFcgRIIIb, butnot toFcgRIIa, comparedwithantibodieswith ahighamountofFc
fucose. Consequently, these antibodies with a low amount of Fc fucose showed enhanced
phagocytosis of platelets usingFcgRIIIb1polymorphonuclear cells or FcgRIIIa1monocytes
as effector cells, but not with FcgRIIIa– monocytes. In addition, the degree of anti-HPA-1a
fucosylation correlated positively with the neonatal platelet counts in FNAIT, and negatively
to the clinical disease severity. In contrast to the FNAIT patients, no changes in core
fucosylationwere observed for anti-HLA antibodies in refractory thrombocytopenia (post platelet transfusion), indicating that the level of
fucosylation may be antigen dependent and/or related to the immune milieu defined by pregnancy. (Blood. 2014;123(4):471-480)
Introduction
Fetal or neonatal alloimmune thrombocytopenia (FNAIT) is a
potentially life-threatening disease where the fetal platelets are
targeted by maternal anti-platelet immunoglobulin G (IgG) alloanti-
bodies crossing the placenta. This leads to IgG-Fc receptor (FcgR)–
mediated uptake by phagocytes in the fetal spleen and liver, ﬁnally
resulting in thrombocytopenia.1 Clinical outcome may differ from
asymptomatic to petechiae or intracerebral hemorrhage. The strength
of the interaction between IgG and FcgR depends on several factors,
including the IgG subclass formed during the immune response, its
relative afﬁnity to FcgRs, the expression levels of FcgR allotypes,
FcgR copy number variation, cytokines (inﬂuencing the expression of
FcgR), and also the IgG-Fc glycosylation pattern.2
IgG antibodies are glycoproteins containing a branched sugar
moiety attached to the Asn297 residue in the Fc part. This glycan is
essential for themaintenance of a functional structure and for binding
of IgG with FcgR.3-5 In addition, the Asn297-linked glycans are
substituted with variable amounts of galactose and sialic acid and
may additionally carry a bisecting N-acetylglucosamine (GlcNAc)
and core fucose. Variation in this composition inﬂuences antibody
afﬁnity to FcgR and thus antibody effector activity. IgG galacto-
sylation has been found to be decreased in several inﬂammatory
diseases (primary osteoarthritis, rheumatoid arthritis, and tuber-
culosis),6,7 as well as in ovarian cancer.8 Interestingly, increase in
galactosylation correlates with remission of arthritis in pregnant
rheumatoid arthritis patients.7,9,10 The degree of IgG galactosylation
has been shown to depend on age and gender; IgG galactosylation is
higher in females at a young age and decreases for both males and
females with increasing age.11,12 In addition, an increase for total IgG
galactosylation has been observed in pregnancy.7,9,10,13 Recently, an
anti-inﬂammatory activity of immune complexes containing highly
Fc-galactosylated mouse IgG1 was reported to enhance the association
of FcgRIIb with dectin-1.14
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Changes related to age, gender, and pregnancy have also been
described for IgG sialylation. Sialylation slightly reduces the
afﬁnity of IgG to FcgRs but enhances the binding to dendritic cell-
speciﬁc intercellular adhesion molecule-3–grabbing nonintegrin (DC-
SIGN), thereby leading to an anti-inﬂammatory response attributable
to increased expression of the inhibitory FcgRIIb.15-17
Importantly, a lack of core fucose has been demonstrated to result
in a stronger binding afﬁnity to FcgRIIIa and FcgRIIIb because of
glycan-glycan interactions between Asn162 found only in FcgRIII
and Asn297 in IgG1.5,18,19 Curiously, although nonfucosylated anti-
bodies clearly enhance the binding to FcgRIIIa and FcgRIIIb, this
only results in enhanced antibody-dependent cellular cytotoxicity on
mononuclear cells through FcgRIIIa,3,20-24 but not through the gly-
cosylphosphatidylinositol (GPI)–linkedFcgRIIIb onpolymorphonuclear
cells (PMNs).18,25 The therapeutic anticancer potential of antibodies with
decreased fucosylation, however, has been well recognized, and their
power is currently being harnessed in clinical trials.18,20-24,26-30
In whites, the main antibodies causing FNAIT are the anti–human
platelet antigen (HPA) 1a antibodies, found in;85%of the cases and in
;1:1500 pregnancies.31-33 The HPA-1a epitope resides in the GPIIIa
protein of the GPIIb/IIIa complex and is missing in individuals with
a single nucleotide polymorphism resulting in an L to P change at
position 33 in the mature protein.31 In a previous study, we reported
a reduced fucosylation, an increased galactosylation, and sialylation of
various anti-platelet IgG1 for a small series of FNAIT sera (including
2 samples with anti-HPA-1a antibodies).32 We now expand this to
a cohort of 48 FNAIT anti-HPA-1a samples. Furthermore, we compare
the glycosylation of IgG formed during immune responses against
platelets in pregnancy with that of IgG formed against HLA after
platelet transfusion or pregnancies. Our main ﬁndings show that Fc
fucosylation is decreased in FNAIT, but not in refractory thrombo-
cytopenia (RT), based on Fc analysis of anti-HPA-1a antibodies and
anti-HLA class I antibodies, respectively, indicating that Fc
fucosylation is regulated. Decreased Fc fucosylation increased
the IgG afﬁnity to FcgRIIIa and FcgRIIIb and also increased
platelet phagocytosis by both monocytes and neutrophils, a key
process in the pathogenesis of FNAIT.
Methods
Patient samples
Anti-HPA-1a platelet alloantibodies were diagnosed at Sanquin (Amsterdam,
The Netherlands; n 5 39), at University Hospital North Norway (Tromso,
Norway; n5 5), and at National Health Service Blood and Transplant (Bristol,
United Kingdom; n 5 4), from maternal FNAIT sera using a monoclonal
antibody immobilization of platelet antigens assay, performed as described by
Kiefel et al.33 TheHLA class I antibodies were all diagnosed at Sanquin (n5 13)
and detected in serum from RT patients (refractory for platelet transfusions),
using the Lifescreen Luminex HLA class I antibody screening method.34 Patient
characteristics for all samples included in the study are listed in supplemental
Table 1 (see the BloodWeb site). Samples were obtained with informed consent
from the patients in accordance with the Declaration of Helsinki.
Purification of anti-platelet antibodies from sera
HPA-1a–speciﬁc alloantibodies were puriﬁed in a similar way as described
previously,32 but now instead of eluting from platelets, we increased the
speciﬁcity by eluting the antibodies with formic acid from antigen-coated
plates (PAK12; Immucor GTI Diagnostics, Waukesha, WI). The same plates
were used for puriﬁcation of anti-HLA class I antibodies. Further details are
described in the supplemental Methods.
Mass spectrometric IgG-Fc glycosylation analysis
Nano liquid chromatography–tandem mass spectrometry was performed as
described in the supplemental Methods.
Production of recombinant anti-TNP IgG1 antibodies with low
and high amounts of Fc fucose
The variable regions of the heavy and light chains (VH, VL) of the mouse
IgG1 anti-2,4,6-trinitrophenol (TNP) hapten antibodies were cloned onto
human IgG1 or k backbone, respectively, as described previously,35 and
produced in the HEK-293F FreeStyle cell line expression system (Life
Technologies, Paisley, United Kingdom), but now in the presence or absence
of 2-deoxy-2-ﬂuoro-L-fucose (2F; Carbosynth, Compton, Berkshire, United
Kingdom) to control the level of fucosylation.36 Antibodies were puriﬁed on
a proteinA (WT IgG1)HiTrapHP column (GEHealthcare Life Sciences, Little
Chalfont, United Kingdom) using the Acta Prime Plus system (GE Healthcare
Life Sciences) and dialyzed against phosphate-buffered saline (PBS) overnight.
IgG-Fc glycosylation was determined by mass spectrometry.
Surface plasmon resonance (SPR)
SPR measurements were performed with the Biacore 3000 system (Biacore
AB, Breda, The Netherlands) at 25°C. Anti-histidine antibody (GE
Healthcare, The Netherlands), 25 mg/mL in sodium acetate buffer pH 4.5
(GE Healthcare), was coupled covalently to a CM5 chip (GE Healthcare)
following activation with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
(Sigma-Aldrich, Zwijndrecht, The Netherlands) 0.4 M in water and
N-hydroxysuccinimide (Sigma-Aldrich) 0.1 M. To measure binding of
monoclonal IgG to FcgRs, 20 ng of human recombinant polyHisTag FcgRIIa
or 10 ng of human recombinant polyHisTag FcgRIIIa (Novoprotein, Summit,
NJ) or 5 ng human recombinant polyHisTag FcgRIIIb (Sino Biologicals Inc.,
Beijing, China), diluted in 0.01MHEPES pH 7.4, 0.15MNaCl, 3 mMEDTA,
0.005% v/v Surfactant P20 buffer (GE Healthcare), was injected, followed by
the injection of anti-TNP IgG at different concentrations. Further details are
described in the supplemental Methods.
Cell isolations, TNP haptenization, labeling, and
antibody opsonization
Human platelets, PMNs, and monocytes were isolated freshly, and platelets
were haptenized with TNP, as described in the supplemental Methods.
Hereafter, platelets were labeled with pHrodo by resuspending a platelet
pellet in 0.23 mM pHrodo succinimidyl ester (100 mL/108 platelets) (Mo-
lecular Probes; Invitrogen, Eugene, OR), in 100 ng/mL Prostaglandin E1, for
45 minutes in the dark at room temperature. Then, the platelets were washed
twice and resuspended in PBS/EDTA/Prostaglandin E1 at 108 platelets permL.
The haptenized and pHrodo-labeled platelets were opsonized by resus-
pending a pellet of platelets with 100 mL of 10 mg/mL anti-TNP antibody low/
high fucose or isotype antibody for every 108 platelets and subsequent in-
cubation for 30 minutes at room temperature. Hereafter, platelets were washed
twice with PBS/bovine serum albumin and resuspended at 108/mL in Normal
Human Serum (NHS).
Similarly, unhaptenized and pHrodo-labeled platelets were opsonized by
resuspending a pellet of platelets with 100mLFNAIT/anti-HPA-1a serumdiluted
to 35 arbitrary units (AU) of anti-HPA-1a antibody (using a human anti-HPA-1a
standard, 100 AU, National Institute for Biological Standards and Control code:
03/152; National Institute for Biological Standards and Control, Hertfordshire,
United Kingdom), for every 108 platelets. NHS was used as isotype control.
Hereafter, the platelets were incubated for 30 minutes at room temperature,
washed twice with PBS, and resuspended at 108/mL in NHS.
Platelet phagocytosis using anti-TNP antibodies or FNAIT
anti-HPA-1a sera
Phagocytosis was carried out using freshly isolated human PMNs or
CD161/CD16– (FcgRIIIa1/ FcgRIIIa–) sorted peripheral monocytes (effector
cells). Equal volumes of 2.0 3 106/mL effector cells and 1.0 3 108/mL
opsonized platelets weremixed in a total volume of 100mL in 1.4-mLU-bottom
tubes (Micronic, Lelystad, The Netherlands) for 20 minutes in a shaking
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incubator at 37°C. After the reaction, the cells were kept on ice and washed in
coldPBS. Samplesweremeasuredwith aﬂowcytometer (LSRII; BDBioscience,
San Jose, CA) and analyzed for colored events using FacsDIVA software (BD
Bioscience). Phagocytosis data were eventually compared with the degree of Fc
fucosylation as determined by mass spectrometry, as described previously.
Results
Fc glycosylation of anti-HPA-1a antibodies formed in FNAIT
Total IgG and anti-HPA-1a antibodies were puriﬁed from 48
maternal anti-HPA-1a FNAIT sera by afﬁnity absorption and elution
on HPA-1a–containing immunosorbent plates, subjected to tryptic
digestion, and the resulting IgG1 Asn297-Fc glycopeptides analyzed
by mass spectrometry. No IgG-Fc glycopeptides were detected when
NHS (without anti-HPA-1a antibodies) were subjected to the anti-
HPA-1a puriﬁcation procedure (data not shown). Likewise, no IgG
glycopeptides were detected when anti-HPA-1a FNAIT sera were
applied to immunosorbent matrices containing irrelevant antigens.
Together, these experiments demonstrate the speciﬁcity of the anti-
HPA-1a IgG1 puriﬁcation procedure. A total of 14 different IgG1-Fc
glycopeptides were monitored (Table 1). For some patients, only
small differences in glycosylation proﬁles of total IgG1 and
anti-HPA-1a IgG1 were observed (example of full glycoproﬁles
in Figure 1A-B), whereas marked differences were observed for
others (example in Figure 1C-D): For total IgG1, the Fc glycosylation
proﬁles were always dominated by fucosylated glycan structures
(G0F, G1F, G2F, and G2FS; Figure 1 A,C); whereas the major
glycoforms registered for anti-HPA-1a IgG1, often (Figure 1D),
but not always (Figure 1B), lacked core fucose (G1, G2, and G2S).
Systematic analysis of the Fc glycosylation with regard to ga-
lactosylation, sialylation, presence of bisecting GlcNAc (bisection),
and fucosylation, comparing the glycosylation of total IgG1 with that
of anti-HPA-1a IgG1 in a pairwise manner, revealed a slight but
signiﬁcant increase in the levels of Fc galactosylation (Figure 2A).
Similar, but less pronounced, increaseswere observed for Fc sialylation
(Figure 2B). As expected, the level of sialylation correlated sig-
niﬁcantly with the level of galactosylation for both total IgG and
speciﬁc HPA-1a antibodies (supplemental Figure 1), as the
galactosylated structures form the substrate for the sialyltrans-
ferase (see Table 1; Figure 1). No signiﬁcant differences were
observed for the bisecting GlcNAc content of anti-HPA-1a antibodies
comparedwith total serum IgG1 (Figure 2C). However, although total
IgG1 contained normal levels of core fucose at Asn297, the majority
of anti-HPA-1a antibody samples showed an overrepresentation of
IgG1 without fucose (Figure 2D).
Maternal IgG samples were taken within a time range of weeks to
years after delivery. However, samples that were taken a prolonged
period after delivery (N5 7) still demonstrated a lowered degree of
anti-HPA-1a fucosylation (speciﬁc IgG1 fucosylation minus total
IgG1 fucosylation; Figure 3).
We hypothesized that this skewing in the IgG response against
platelets in FNAIT patients may also affect glycosylation features
other than fucosylation. We therefore investigated whether the
degree of anti-HPA-1a fucosylation correlates with the degree of
bisection, galactosylation, and sialylation. We observed a weak but
signiﬁcant positive correlation between anti-HPA-1a fucosylation
and bisection (R25 0.112) and a negative correlation between anti-
HPA-1a fucosylation and galactosylation (R2 5 0.200), whereas
there was no signiﬁcant correlation between anti-HPA-1a fucosy-
lation and sialylation (supplemental Figure 2).
Fc glycosylation of anti-HLA antibodies
To investigate whether the skewing of glycosylation seen in anti-
platelet responses during pregnancies was attributable to a general
anti-platelet response or to an anti-HPA-1a–related response in preg-
nancy, we also investigated the IgG responses formed against platelets
in sera of 13 RT patients (lack of adequate posttransfusion platelet-
count increments, in which anti-HLA antibodies are frequently
implicated). Similar to the anti-platelet responses in FNAIT, we found
the anti-HLA Fc galactosylation in RT to be increased compared with
total serum IgG1 levels (Figure 4A). Unlike the FNAIT samples, no
speciﬁc increaseswere observed for Fc sialylation (Figure 4B), and the
bisecting GlcNAc content of the anti-HLA antibodies was signiﬁ-
cantly decreased (Figure 4C). Also, in contrast to the Fc fucosylation
of anti-HPA-1a antibodies, the anti-HLAFc fucosylation did not show
any changes compared with total serum IgG1 (Figure 4D). In addition,
we investigated an FNAIT anti-HPA-1a sample, which also contained
anti-HLA antibodies. The anti-HPA-1a antibodies displayed a mark-
edly lowered degree of fucosylation (43% as compared with 94% for
total IgG1), whereas the anti-HLA antibodies from the same sample
were not skewed in fucosylation (87%; supplemental Figure 3).
IgG with low Fc fucose has increased binding affinity to
FcgRIIIa and FcgRIIIb
To test the biological inﬂuence of the lowered Fc fucosylation of IgG
antibodies in the clearance of platelets, we produced TNP-speciﬁc
Table 1. Theoretical mass-to-charge ratios (m/z) of human IgG1-Fc
glycopeptides detected by nano-liquid chromatography–electrospray
ionization-mass spectrometry
Glycan species* Structural scheme† Theoretical glycopeptide m/z
G0 830.00
G0F 878.69
G1 884.02
G1F 932.71
G2 938.04
G0FN 946.38
G2F 986.72
G1FN 1000.40
G2FN 1054.42
G1FS 1029.74
G2S 1035.07
G2FS 1083.75
G1FNS 1097.43
G2FNS 1151.45
The observed tryptic IgG1-Fc glycopeptides have a common peptide moiety (p)
of E293EQYNSTYR301 (Swiss-Prot entry number P01857). The m/z values of the
triple protonated species are given.
*Glycan structural features are given in terms of number of galactoses (G0, G1,
G2), fucose (F), bisecting N-acetylglucosamine (N), and N-acetylneuraminic acid
(sialic acid) (S).
†Blue square indicates N-acetylglucosamine; green circle, mannose; yellow circle,
galactose; purplediamond,N-acetylneuraminic acid (sialic acid); and red triangle, fucose.
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antibodies in HEK-293F FreeStyle cells in the absence or presence
of 2F, which has recently been described to deplete the level of
guanosine diphosphate fucose, the substrate of fucosyltransferases,
and thereby prevent fucose incorporation into proteins.36 In agree-
ment with those results, addition of 100, 200, and 400 mM resulted
in a dramatic reduction of core fucose incorporation into IgG,
dropping from 76% fucosylation to 14%, 8%, and 6%, respectively
(supplemental Figure 4). For the following experiments, the 76%
fucosylated sample was used as anti-TNP high fucose, and the 6%
fucosylated sample was used as anti-TNP low fucose. In accordance
with the unique presence of Asn162 in the human FcgRIII family,
required for glycan-glycan interaction of IgG and FcgR,5we observed
Figure 1. Mass spectrometric analysis of Fc glycopeptides of total IgG1 and anti-HPA-1a IgG1 from 2 pregnant women. One person showed high degrees of fucosylation
for total IgG1 (97%;A) and anti-HPA-1a IgG1 (86%;B). The other also showed a high degree of fucosylation for total IgG1 (86%; C), yet a lowdegree of fucosylation for anti-HPA-1a
IgG1 (9%; D). Major fucosylated glycoforms are labeled in red, and nonfucosylated glycoforms are labeled in blue or are unlabeled. Blue square indicatesN-acetylglucosamine; red
triangle, fucose; green circle, mannose; yellow circle, galactose; purple diamond, N-acetylneuraminic acid; pep, peptide moiety; and asterisk, contaminant. Triple-protonated
glycopeptide signals were observed throughout. For the assignment of the glycopeptides signals, see Table 1. The level of galactosylation, sialylation, bisection (bisecting
N-acetylglucosamine), and fucosylation were calculated according to the following formulas: Galactosylation5 (G1F1G1FN1G1FS1G1FNS1G1)3 0.51G2F1G2FN1
G2FS1G2FNS1G21G2S. Agalactosylated structures5G0F1G0FN1G0.Digalactosylated structures5G2F1G2FN1G2FS1G2FNS1G21G2S.Sialylation5G1FS1
G2FS1G1FNS1G2FNS1 G2S. Bisection5 G0FN1G1FN1G2FN1G1FNS1G2FNS. Fucosylation5 G0F1 G1F1G2F1G0FN1G1FN1G2FN1G1FS1G2FS.
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that the lack of core fucosylation dramatically increased the binding
afﬁnity to FcgRIIIa and FcgRIIIb but not FcgRIIa (Table 2).
Lack of IgG core fucosylation increases platelet phagocytosis
We next TNP-haptenized platelets, labeled them with pHrodo
(only ﬂuorescent in acid environment), and opsonized them with
the anti-TNP antibody. For both PMNs and CD161 monocytes,
expressing FcgRIIIb or FcgRIIIa, respectively, fucosylated anti-
bodies resulted in low platelet ingestion; whereas low-fucosylated
antibodies showed a signiﬁcantly increased phagocytic response
with both effector cell types (Figure 5A-B). However, CD16– mono-
cytes showed no preference for low- or high-fucosylated antibodies
for platelet phagocytosis, in accordance with their lack of FcgRIIIa
expression (Figure 5C).
Phagocytosis was also performed using anti-HPA-1a antibodies
from 7 FNAIT sera. Platelets were labeled with pHrodo, opsonized
with 35 AU of anti-HPA-1a antibody derived from maternal
FNAIT sera, and subjected to phagocytosis by PMNs. The degree
of phagocytosis correlated signiﬁcantly with the degree of anti-
HPA-1a Fc fucosylation (P 5 .023, R2 5 0.590; Figure 5D).
A lowered anti-HPA-1a Fc fucosylation correlates with
decreased neonatal platelet counts and increased disease
severity in FNAIT patients
We then investigated if core fucosylation of the HPA-1a antibodies
affected the disease outcome clinically. A signiﬁcant correlation
between neonatal platelet counts, obtained directly after delivery, and
the degree of anti-HPA-1a fucosylation was found in the FNAIT
patients, with lowered anti-HPA-1a Fc fucosylation corresponding
to low neonatal platelet counts (Figure 6A; P 5 .043, r 5 0.320).
We also found a signiﬁcant correlation between the degree of anti-
HPA-1a fucosylation and the clinical disease severity directly after
delivery (ranging from asymptomatic to mild symptoms such as
petechiae, to moderate symptoms including organ bleeding, to
severe symptoms such as intracranial hemorrhages; Figure 6B;
P 5 .020, r 5 –0.377). A lowered degree of anti-HPA-1a
Figure 2. Anti-HPA-1a antibodies in FNAIT display
a pronounced lowering of Fc fucosylation. Relative
expression levels of major IgG-Fc Asn297 glycoforms
for both total IgG1 (x-axis) and antigen-specific IgG1
(y-axis) for 48 FNAIT anti-HPA-1a serum samples (A-D).
Serum populations were analyzed for Fc galactosyla-
tion (A), sialylation (B), bisection (C), and fucosylation
(D). The statistical outcome between 2-tailed paired
Student t test analysis of total IgG1 vs specific antibodies
is listed in each panel. The diagonal, dotted line
represents the equal ratio between total IgG1 and
the specific antibody.
Figure 3. FNAIT anti-HPA-1a antibodies with decreased fucosylation are
present years after delivery. The degree of anti-HPA-1a Fc fucosylation (specific
IgG1 fucosylation minus total IgG1 fucosylation) is plotted against the time after
delivery, for 7 anti-HPA-1a FNAIT samples (period of 6 weeks to 7 years postdelivery).
BLOOD, 23 JANUARY 2014 x VOLUME 123, NUMBER 4 LOW Fc FUCOSE OF ANTI-HPA-1a ANTIBODIES IN PREGNANCY 475
For personal use only.on June 3, 2016. by guest  www.bloodjournal.orgFrom 
fucosylation corresponded to more severe clinical disease severity,
with all asymptomatic patients bearing a high level of IgG-Fc core
fucosylation (on average 85%; Figure 6B).
Discussion
In this study, we analyzed a large FNAIT serum cohort consisting of
48 serum samples, all containing anti-platelet alloantibodies formed
during pregnancy and directed against the most common immuno-
genic alloantigen on platelets, the HPA-1a epitope of glycoprotein
IIb/IIIa. The glycosylation patterns of anti-HPA-1a IgG1 antibodies
were compared with those of total IgG1 antibodies within the same
individual and to anti-platelet antibodies formed after platelet
transfusion in RT patients with anti-HLA antibodies. Antigen-
speciﬁc antibodies were afﬁnity puriﬁed using surface-immobilized
antigen, and the tryptic Fc glycopeptides of the pathogenic IgG1 as
well as of total IgG1 were analyzed by mass spectrometry. The Fc-
glycosylation patterns of both FNAIT and RT cohorts of anti-
platelet or anti-HLA antibodies displayed a slight, but signiﬁcant,
increase in the level of galactosylation. Only in the FNAIT group
did we ﬁnd anti-GPIIIa antibodies with a slight, but signiﬁcant,
increase in the level of sialylation, and only in the RT patient group
did we ﬁnd a slight decrease in the level of bisecting GlcNAc of the
anti-HLA antibodies. The main difference between the patient
groups was observed for core fucosylation, with the majority of the
FNAIT patients with anti-HPA-1a–speciﬁc antibodies showing
a markedly lowered IgG1-Fc fucosylation in pregnancy (levels
down to 10% fucosylation), a very atypical form of IgG-Fc
glycosylation (normal values being .90%).13,37 To our knowl-
edge, a lowered fucosylation has only been found for HIV-speciﬁc
antibodies in elite controllers of HIV infection, but unlike in
our study, these also displayed agalactosylated and asialylated
glycans.38
We further observed normal high levels of core fucosylation for
anti-HLA class I antibodies (RT patients), of which 12 of the 13
patients were women who we cannot exclude to have been
immunized already during a previous pregnancy. Our previous study
also featured patients (N5 2) with anti-HPA-1a antibodies (normally
Figure 4. Anti-HLA antibodies in RT do not display
a pronounced lowering of Fc fucosylation. Relative
expression levels of major IgG-Fc Asn297 glycoforms
for both total IgG1 (x-axis) and antigen-specific IgG1
(y-axis) for 13 RT anti-HLA class I serum samples
(A-D). Serum populations were analyzed for Fc galacto-
sylation (A), sialylation (B), bisection (C), and fucosylation
(D). The statistical outcome between 2-tailed paired
Student t test analysis of total IgG1 vs specific antibodies
is listed in each panel. The diagonal, dotted line rep-
resents the equal ratio between total IgG1 and the
specific antibody.
Table 2. Decreased Kd values for anti-TNP low-fucose antibodies
compared with anti-TNP high-fucose antibodies with respect to
FcgRIIIa and FcgRIIIb, but not for FcgRIIa
FcgRIIIa
(Kd, mM) 6 SD
FcgRIIIb
(Kd, mM) 6 SD
FcgRIIa
(Kd, mM) 6 SD
Anti-TNP high fucose 0.12 6 0.01 0.58 6 0.11 0.22 6 0.11
Anti-TNP low fucose 0.05 6 0.02 0.08 6 0.00 0.20 6 0.08
Paired Student t test
anti-TNP high fucose vs
anti-TNP low fucose
0.001, *** 0.008, ** 0.2252, NS
SPR analyses of anti-TNP antibodies with high fucose vs anti-TNP antibodies
with low fucose, interacting with FcgRIIIa (n5 3), FcgRIIIb (n5 3), and FcgRIIa (n5 4).
Kd values (mM): the constant rate of dissociation of antibody from the receptors at
equilibrium state, with standard deviation (SD) are shown. One-tailed paired-test
outcome is depicted. **P # .01; ***P # 001. NS, nonsignificant.
476 KAPUR et al BLOOD, 23 JANUARY 2014 x VOLUME 123, NUMBER 4
For personal use only.on June 3, 2016. by guest  www.bloodjournal.orgFrom 
observed in FNAIT patients) formed after transfusion, and they also
did not display a skewing in core fucosylation.32 Because other
glycosylation patterns were affected as well, we hypothesize that this
kind of IgG response must be governed by the very settings under
which these antibodies are formed: either the T helper 2–dominant
features of pregnancies,39 the anti-platelet response, the anti-HPA-1a
response, or a combination of these factors. We also investigated an
FNAIT anti-HPA-1a sample, which also contained anti-HLA anti-
bodies, with lowered Fc fucosylation for the anti-HPA-1a antibodies,
but not for the anti-HLAantibodies. Togetherwith the data on normal
fucosylation of anti-HLA antibodies from theRTpatients, this further
lends support to the hypothesis that other factors besides pregnancy
are involved in this type of IgG fucosylation.
Among the 48 FNAIT samples analyzed, 7 samples were taken in
a period ranging from 6weeks to 7 years after delivery;whereas all the
other samples were taken within 2 days after delivery. Surprisingly,
the lower levels of IgG fucose (speciﬁc values of relative abundance
minus total values) seemed to persist for a prolonged period after
delivery, indicating that the type of IgG glycosylation acquired during
the onset of the immune response is a subject of imprinting or
attributable to long-lived plasma cells.
The increased levels of speciﬁc galactosylation of antigen-
speciﬁc IgG1 compared with total IgG1 in the cohorts with anti-
HPA-1a antibodies developed after pregnancies and anti-HLA
antibodies in platelet-transfused patients appear to be, to our
knowledge, the ﬁrst disease settings in which this phenomenon
is described. A high degree of galactosylation has been found
to negatively affect IgG half-life in mice,40 suggesting that
galactosylation may also inﬂuence the transport of IgG from
mother to child because both half-life and transport of IgG are
mainly mediated by the neonatal Fc receptor FcRn.41 However, no
such skewing for IgG transport across the human placenta was
found in our previous study,42 in accordance with the fact that the
Fc glycans are not involved in binding to FcRn.43 The increased
levels of galactosylation and sialylation observed for the anti-
HPA-1a antibodies in FNAIT might also enable a downregulation
of the immune response, opposing the stimulatory effect caused by
a decreased anti-HPA-1a fucosylation.
Various B-cell stimuli have been shown to modulate Fc
glycosylation. Both the Toll-like receptor 9 ligand cytosine
guanine dinucleotide oligodeoxynucleotide and interleukin 21
have been shown to increase Fc galactosylation and reduce bisecting
GlcNAc levels. In contrast, all-trans retinoic acid decreases
galactosylation and sialylation levels.44 Recently, T-cell in-
dependent B-cell activation has also been shown to induce im-
munosuppressive sialylated IgG antibodies in mouse models.45
In the present study, we observed increased levels of galacto-
sylation and lowered levels of fucosylation. This may perhaps be
regulated via a higher expression of b4-galactosyltransferase and
a downregulation of fucosyltransferase 8 (FUT8) in the anti-HPA-
1a–producing plasma cells in the FNAIT patients. For HIV-speciﬁc
antibodies, which also displayed decreased fucosylation, FUT8
expression was found to be decreased in controllers and treated
Figure 5. Absenceof IgG-Fccore fucose enhancesplatelet phagocytosis through
FcgRIII on PMNs and monocytes. Platelets were haptenized with TNP; labeled for
phagocytosis with pHrodo; opsonizedwith either isotype antibody, anti-TNP low- or high-
fucose antibodies; subjected to phagocytosis by either neutrophils (PMNs; A), FcgRIIIa1
monocytes (B), or FcgRIIIa– monocytes (C) as effector cells; and expressed as anti-
TNP–specific phagocytosis (Mean Fluorescence Intensity (MFI) anti-TNP2MFI isotype
IgG). Anti-TNP IgG1 antibodies with low fucose displayed increased phagocytosis
compared with highly fucosylated anti-TNP antibodies using PMNs or FcgRIIIa1
Figure 5 (continued) monocytes (A-B, respectively) as effector cells, but not with
FcgRIIIa– monocytes (C). Platelets were labeled with pHrodo, opsonized with 35 AU of
anti-HPA-1a antibodies from maternal FNAIT sera, and subjected to phagocytosis by
neutrophils (D). Phagocytosis was expressed as anti-HPA-1a–specific phagocytosis
(MFI anti-HPA-1a from maternal FNAIT sera 2 MFI isotype IgG from NHS). Statistical
analyses: 1-tailed unpaired Student t test (A-C) and Pearson correlation (D). *P # .05;
**P # .01. NS, nonsignificant.
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progressors compared with untreated progressors, whereas the
expression of the fucosidase FUCA2was found to be increased in
controllers and untreated subjects.38 Recently, the transcription
factor hepatocyte nuclear factor (HNF) 1a and its downstream target
HNF4a have been identiﬁed as transcriptional regulators of key
fucosyltransferases and fucose biosynthesis genes.46 However, the
exact stimuli and the regulatory pathways have yet to be elucidated.
Also, the degree of anti-HPA-1a fucosylation demonstrated a low
but statistically signiﬁcant positive correlation with the level of
bisecting GlcNAc, as well as a negative correlation with the level
of galactosylation. This indicates that the glycosylation of the IgG
antibodies is dictated by the speciﬁc immune reaction, forming
a differential spectrum of Fc-glycosylated antibodies that depends
on the nature of the immune response.
FcgRIIIa is expressed either with valine or phenylalanine at
position 158, with the V variant showing a stronger afﬁnity for IgG1
and IgG3.47,48 The expression of the higher-afﬁnity form (V158)
is associated with higher incidence of inosine 59-triphosphate, sug-
gesting that this receptor may be highly relevant for the clearance
of platelets.49 In FNAIT, the decreased Fc fucosylation of anti-
platelet alloantibodies most likely contributes to enhanced platelet
phagocytosis via increased Fc receptor interaction, as we conﬁrmed
by biosensor analysis and by phagocytosis of platelets. The in-
creased afﬁnity was seen only for FcgRIIIa, expressed on a subset
of monocytes, macrophages, and natural killer cells; for FcgRIIIb,
expressed on granulocytes; but not for other FcgR receptor types
because these do not express the glycan found at position 162, only
found in both FcgRIII types.5 The glycan attached to Asn162 in
FcgRIII has been shown to interact directly with the IgG-Fc glycan,
which is critically inﬂuenced by the presence or absence of the core
fucose. In the latter case, this also allows for binding of the Fc-
protein moiety to FcgRIII, which does not take place when fucose is
present.5 In accordance, both neutrophils and FcgRIII1 (;5% of
peripheral) monocytes showed strong phagocytosis only with low-
fucosylated IgG; whereas FcgRIII– monocytes, the majority of
monocytes in peripheral blood, showed no preference for
platelets opsonized with either high- or low-fucosylated anti-
bodies. In addition, we found the degree of FNAIT anti-HPA-1a Fc
fucosylation to correlate signiﬁcantly with the degree of platelet
phagocytosis, with sera containing less core fucosylation in their
anti-HPA-1a antibodies giving rise to stronger phagocytosis. In line
with this, we also found the degree of anti-HPA-1a Fc fucosylation
to correlate positively with neonatal platelet counts directly after
delivery.
The association of the functional single nucleotide polymorphism
within FcgRIIIa with the higher incidence of inosine 59-triphosphate
ﬁts with data demonstrating that the spleen is the most important site
for IgG-opsonized platelet clearance by residing splenic macro-
phages and/or monocytes (that uniformly express FcgRIIIa). This
suggests that fucosylation of anti-platelet antibodies plays an im-
portant role. In support of this, we found anti-HPA-1a Fc-fucosylation
levels to correlate negatively with the clinical disease severity in
FNAIT. Although our FNAIT cohort is limited by the fact that most
asymptomatic anti-HPA-1a patients remain undiagnosed, our study
did include a few patients who were asymptomatic directly after
delivery. All of these asymptomatic patients demonstrated high levels
of anti-HPA-1a Fc fucosylation. Fucosylation status of anti-platelet
antibodies may therefore prove to be a useful diagnostic marker to
evaluate disease severity. However, and perhaps somewhat re-
markably, the function of the anti-HLA antibodies from RT
patients, all with normal fucosylation, seems less affected by their
fucosylation because they apparently are fully capable of causing
potent platelet destruction. However, other factors, such as titer,
should also be taken into account, but also the FcgR most strongly
involved in the destruction. For anti-HPA-1a antibodies, this
appears to be FcgRIIIa, the function of which is highly sensitive
to core fucosylation; however, for anti-HLA class I antibodies,
this may be a different FcgR not sensitive to changes in core
fucosylation.
In conclusion, the Fc glycosylation of anti-platelet antibodies in
FNAIT and RT is associated with a slightly increased level of Fc
galactosylation that predisposes the IgG for further modiﬁcation by
the addition of sialic acid. In FNAIT, an additional IgG modiﬁcation
frequently appears in the form of a very pronounced decrease of Fc
fucosylation, resulting in increased binding afﬁnity to FcgRIIIa and
FcgRIIIb, as well as increased platelet phagocytosis by PMNs or
FcgRIIIa1monocytes. This is also reﬂected by the positive correlation
between the degree of anti-HPA-1a Fc fucosylation and the neonatal
platelet counts in FNAIT. In addition, the extent of reduced Fc
fucosylation of anti-HPA-1a correlated signiﬁcantly with more severe
bleeding tendency. In contrast,wedonot see this decreased fucosylation
phenomenon for anti-HLA antibodies in RT, strongly suggesting that
IgG glycosylation, and therefore its functional potential, is under
tight regulation in humans.
Figure 6. Degree of fucosylation correlateswith neonatal platelet counts in FNAIT
and clinical severity. Degree of fucosylation was compared with neonatal platelet
counts in FNAIT directly after delivery (A), as well as with the clinical disease severity
score (B). The scores are as follows: 0 indicates no symptoms; 1, mild symptoms
(petechiae); 2, moderate symptoms (other bleeding, including organ bleeding); and 3,
severe symptoms (intracranial hemorrhages) (B). Statistical analyses were performed
using Spearman rank correlation, with a positive correlation in panel A (r 5 0.320) and
a negative correlation in panel B (r 5 20.377). *P # .05.
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